ViroCyt
Recent News
-
ViroCyt Completes Second Close of Growth Capital Financing
DENVER, CO–(Marketwire – April 3, 2013) – ViroCyt, LLC, the leader in the field of rapid virus quantification, today announced the addition of new investors to its most recent round of funding. This financing was an extension of the initial close, which occurred on November 14, 2012, resulting in a total raise of approximately $5 Continue Reading »
Read More
-
Jack Ball Joins ViroCyt Board
DENVER, CO–(Marketwire – Feb 19, 2013) – ViroCyt, LLC, a life sciences company providing breakthrough analytical technologies, today announced the appointment of Jack T. Ball, Jr. to its Board. Mr. Ball previously served as Chief Commercial Officer at Accuri Cytometers, Inc., where he was responsible for worldwide sales, marketing and business development of flow cytometers. During this Continue Reading »
Read More
-
ViroCyt Begins Operations
InDevR Spins Off ViroCyt, Raises Growth Capital. DENVER, CO–(Marketwire – January 15, 2013) - ViroCyt, LLC, a privately-held life science company, announced today that it had begun operations after spinning off from InDevR, Inc. Concurrent with the formation of ViroCyt, funding was secured from a group of investors led by High Country Venture, a Colorado Venture Continue Reading »
Read More
Upcoming Events
NCI-Frederick/Fort Detrick Biomedical Research Equipment & Supplies Exhibit Event Details
Vaccine Development & Production Summit Event Details
Bioprocessing Summit Event Details
Vaccine World China Event Details
World Vaccine Congress France Event Details